Patients
Between April 23, 2020, and October 21, 2022, a total of 70 patients were screened for eligibility, with 46 being enrolled in the study (Fig. 1). Patients received onatasertib at doses of 15 mg (n = 15), 20 mg (n = 17), and…
Multicenter phase 1/2 study of onatasertib, a dual TORC1/2 inhibitor, combined with the PD-1 antibody toripalimab in advanced solid tumors
